These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31748880)

  • 1. Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs.
    Ding L; Lu S; Li Y
    Pathol Oncol Res; 2020 Apr; 26(2):651-663. PubMed ID: 31748880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
    Smolle MA; Calin HN; Pichler M; Calin GA
    FEBS J; 2017 Jul; 284(13):1952-1966. PubMed ID: 28132417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
    Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
    Liu M; Sun Q; Wei F; Ren X
    Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
    Topalian SL; Drake CG; Pardoll DM
    Curr Opin Immunol; 2012 Apr; 24(2):207-12. PubMed ID: 22236695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
    Jiang W; Pan S; Chen X; Wang ZW; Zhu X
    Mol Cancer; 2021 Sep; 20(1):116. PubMed ID: 34496886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway.
    Awadasseid A; Wu Y; Zhang W
    Life Sci; 2021 Oct; 282():119813. PubMed ID: 34256042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
    Dahan R; Sega E; Engelhardt J; Selby M; Korman AJ; Ravetch JV
    Cancer Cell; 2015 Sep; 28(3):285-95. PubMed ID: 26373277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
    Naidoo J; Page DB; Li BT; Connell LC; Schindler K; Lacouture ME; Postow MA; Wolchok JD
    Ann Oncol; 2015 Dec; 26(12):2375-91. PubMed ID: 26371282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
    Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
    Kalantari Khandani N; Ghahremanloo A; Hashemy SI
    J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.
    Zhulai G; Oleinik E
    Scand J Immunol; 2022 Mar; 95(3):e13129. PubMed ID: 34936125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.